The BC Drug and Poison Information Centre handled 95 cases of bupropion (Wellbutrin, Zyban) exposure in 2013. Eighty-one cases involved adults, with 22 therapeutic errors, 47 cases of suspected suicide, and 9 cases of misuse or abuse. Sixty-four cases were referred to hospital and 22 were admitted to critical care. There was one death. There were 11 exposures in older children and adolescents, including 9 suicide attempts. More than half experienced moderate to severe effects and two patients were admitted to critical care. There were three unintentional exposures in children 5 years and younger; all were referred to hospital for observation.
Bupropion has antidepressant effects and reduces nicotine craving by stimulating release and blocking reuptake of dopamine and norepinephrine, and antagonizing nicotinic receptors. Bupropion is a cathinone derivative, a class of amphetamine-like chemicals that includes the recreational substances referred to as bath salts.
US poison control centres reported 6000 bupropion exposures over a 7-year period in young children. Tachycardia, irritability, drowsiness, ataxia, hallucinations, lethargy, and tremor were seen with doses of bupropion up to 10 mg/kg. A single patient in this dose range developed seizures. The occurrence of seizures or coma increased with higher doses. Buehler and colleagues recommended referral to a health care facility if the ingested dose was greater than 10 mg/kg (a single tablet in a small child) or if the dose was unknown.
In a review of adult medication errors involving bupropion, the median dose ingested was 300 mg (mostly sustained release). Frequent adverse effects were agitation, dizziness, tremor, GI upset, drowsiness, and tachycardia, occurring in 6% to 8% of patients, with seizures in 0.8% and hallucinations in 0.4%. Almost 25% of patients were evaluated at a health care facility. Multiple brand names and indications contributed to errors. In one case report, a patient developed confusion, agitation, and a seizure after unknowingly taking Wellbutrin, Zyban, and generic bupropion for a total of 600 mg bupropion per day.
While bupropion’s abuse potential is low for most patients, reports of recreational use by ingestion and insufflation or snorting began appearing on the popular user experience website, Erowid.org, in 2001. The first report of recreational use of bupropion in medical literature appeared in 2002 and involved ingestion of 600 mg bupropion. This was followed soon after by reports of nasal insufflation, with users reporting amphetamine- or cocaine-like highs, and adverse effects ranging from nasal pain to irritability, aggression, hallucinations, and seizures. Most patients had a history of substance abuse.[6,7] Snorting the substance, referred to as welbys, wellies, dubs, or barnies (due to the purple color), has led to the removal of bupropion from some US prison formularies.[8,9]
Intravenous abuse has also been reported and has resulted in severe skin lesions, vascular complications, and death.
If you suspect an overdose, call the BC Drug and Poison Information Centre at 604 682-5050 or 1 800 567-8911.
—Raymond Li, BSc(Pharm), MSc
BC Drug and Poison Information Centre
This article is the opinion of the BC Centre for Disease Control and has not been peer reviewed by the BCMJ Editorial Board.
1. Beuhler MC, Spiller HA, Sasser HC. The outcome of unintentional pediatric bupropion ingestions: A NPDS database review. J Med Toxicol 2010;6:4-8.
2. Shepherd G. Adverse effects associated with extra doses of bupropion. Pharmacoetherapy 2005;25:1378-1382.
3. Grissinger M. A medication-error trifecta! P&T 2006;31:244.
4. Erowid Center. Defined and memorable: Bupropion (Wellbutrin). Accessed 29 September 2014. www.erowid.org/experiences/exp.php?ID=7185.
5. McCormick J. Recreational bupropion abuse in a teenager. Br J Clin Pharmacol 2002;53:214.
6. Kim D, Steinhart B. Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM 2010;12:158-161.
7. Reeves RR, Ladner ME. Additional evidence of the abuse potential of bupropion. J Clin Pyschopharmacol 2013;33:584-585.
8. Hilliard WT, Barloon L, Farley P, et al. Bupropion diversion and misuse in the correctional facility. J Correct Health Care 2013;19:211-217.
9. Phillips D. Wellbutrin®: Misuse and abuse by incarcerated individuals. J Addict Nurs 2012;23:65-69.
10. Baribeau D, Araki KF. Intravenous bupropion: A previously undocumented method of abuse of a commonly prescribed antidepressant agent. J Addict Med 2013;7:216-217.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org